TORONTO, April 3, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ: GBNH) ("Greenbrook" or the "Company") today announced that the Company has amended its amended and restated master sales agreement ...
Neuronetics said the FDA cleared its transcranial magnetic stimulation (TMS) device, NeuroStar, as an adjunct therapy for the first-line treatment of major depressive disorder in individuals ages 15 ...
The US Food and Drug Administration (FDA) granted 510K clearance to market a new transcranial magnetic stimulation (TMS) device, the MagVita TMS Therapy system from MagVenture, for treatment of adults ...
An advanced version of a procedure using magnetic fields to stimulate brain nerve cells in treating depression was significantly effective for 85% of active military and veterans suffering from combat ...
Most people think of brain health in terms of MRI and CT scans, but QuantalX is marrying transcranial magnetic stimulation with EEG such that clinicians can now measure individual brain function ...
83% of patients who complete Transcranial Magnetic Stimulation treatment experience measurable relief and 62% experience full remission of depression symptoms The expanded label positions Neuronetics' ...
NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...
New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sharing patient and provider stories that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results